CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks
NCT04656418
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
64
Enrollment
INDUSTRY
Sponsor class
Conditions
Hereditary Angioedema
Interventions
BIOLOGICAL:
CSL312
DRUG:
Placebo
Sponsor
CSL Behring